{"id":10698,"date":"2018-05-28T14:07:32","date_gmt":"2018-05-28T12:07:32","guid":{"rendered":"https:\/\/frezzapartners.com\/?p=10698"},"modified":"2018-05-28T14:07:32","modified_gmt":"2018-05-28T12:07:32","slug":"global-oncology-trends-lultimo-report-di-iqvia-institute","status":"publish","type":"post","link":"https:\/\/frezzapartners.com\/en\/global-oncology-trends-lultimo-report-di-iqvia-institute\/","title":{"rendered":"Global Oncology Trends. L\u2019ultimo report di IQVIA Institute"},"content":{"rendered":"<p>Photo by Stephen Walker<\/p>\n<p>&nbsp;<\/p>\n<p>Pi\u00f9 di 700 aziende sono impegnate oggi nella ricerca oncologica. In particolare risultano quattordici le top companies con la maggior parte della pipeline focalizzata su tale area (almeno un terzo).\u00a0 Per quanto concerne gli studi di ricerca, questi sono concentrati specialmente su immunoterapie, con circa trecento molecole e sessanta meccanismi d\u2019azione in valutazione nei trial di fase I e II. Settecento sono i farmaci in pipeline oncologica.<\/p>\n<p>Ecco ci\u00f2 che emerge dal report di IQVIA Insitute &#8211; leader mondiale nella raccolta ed elaborazione di dati nel settore farmaceutico &#8211; sull\u2019evoluzione e il trend delle terapie oncologiche.<\/p>\n<p>In particolare, negli ultimi cinque anni, risultano 63 i farmaci antitumorali &#8211; ciascuno approvato per la terapia di uno o pi\u00f9 tumori &#8211; che hanno avuto un impatto sul trattamento di diversi tipi di cancro (24). L&#8217;incremento delle terapie immuno-oncologiche \u00e8 stato prevalentemente incentrato sui meccanismi PD-1 e PD-L1, i cosiddetti inibitori del checkpoint, che hanno dimostrato un\u2019ampia efficacia sui tumori solidi e vengono usati in 23 differenti tipologie di neoplasie.<\/p>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-10699 aligncenter\" src=\"http:\/\/www.management-planet.it\/wp-content\/uploads\/2018\/05\/Chart-3-New-Active-Substance-Approvals-in-Oncology-by-Indication-2013-2017.png\" alt=\"\" width=\"846\" height=\"838\" srcset=\"https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/Chart-3-New-Active-Substance-Approvals-in-Oncology-by-Indication-2013-2017.png 1352w, https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/Chart-3-New-Active-Substance-Approvals-in-Oncology-by-Indication-2013-2017-350x347.png 350w, https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/Chart-3-New-Active-Substance-Approvals-in-Oncology-by-Indication-2013-2017-100x100.png 100w, https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/Chart-3-New-Active-Substance-Approvals-in-Oncology-by-Indication-2013-2017-150x150.png 150w, https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/Chart-3-New-Active-Substance-Approvals-in-Oncology-by-Indication-2013-2017-300x297.png 300w, https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/Chart-3-New-Active-Substance-Approvals-in-Oncology-by-Indication-2013-2017-768x761.png 768w, https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/Chart-3-New-Active-Substance-Approvals-in-Oncology-by-Indication-2013-2017-1024x1014.png 1024w, https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/Chart-3-New-Active-Substance-Approvals-in-Oncology-by-Indication-2013-2017-50x50.png 50w\" sizes=\"auto, (max-width: 846px) 100vw, 846px\" \/><\/p>\n<p>Dei 14 nuovi farmaci oncologici lanciati lo scorso anno, tutti risultano terapie mirate e 11 di essi hanno ottenuto la designazione di \u201c<em>breakthrough therapy<\/em>\u201d da parte della Fda, per aver dimostrato un potenziale e significativo miglioramento rispetto alle terapie esistenti.<\/p>\n<p>Per quanto riguarda le terapie \u201cdi nuova generazione\u201d, queste iniziano anche a includere anche le terapie geniche e cellulari. Tra queste, ricordiamo i <a href=\"http:\/\/www.management-planet.it\/magazine\/le-terapie-cellulari-car-t-cosa-sono-e-come-funzionano\/\">farmaci CAR-T<\/a> che sfruttano le cellule T di un paziente per combattere il tumore.<\/p>\n<p>Secondo i dati di IQVIA sulla spesa per tumori nel 2017, questa \u00e8 salita a $ 133 mld, rispetto ai $ 96 mld del 2013, (compresa la quota-spesa per le cure di supporto) e crescer\u00e0 mediamente del 10-13% nei prossimi anni. Il costo delle terapie si \u00e8 decisamente innalzato negli ultimi anni, anche se i nuovi farmaci vengono utilizzati su popolazioni sempre pi\u00f9 ridotte di pazienti (e sempre pi\u00f9 frequentemente le malattie tumorali rientrano nelle <em>rare diseases)<\/em>. Basti pensare che la grande parte delle autorizzazioni del 2017 ha avuto indicazione orfana.<\/p>\n<p>Per il download del report completo <a href=\"https:\/\/www.iqvia.com\/institute\/reports\/global-oncology-trends-2018\">clicca qui<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Photo by Stephen Walker &nbsp; Pi\u00f9 di 700 aziende sono impegnate oggi nella ricerca oncologica. In particolare risultano quattordici le top companies con la maggior parte della pipeline focalizzata su tale area (almeno un terzo).\u00a0 Per quanto concerne gli studi di ricerca, questi sono concentrati specialmente su immunoterapie, con circa trecento molecole e sessanta meccanismi d\u2019azione in valutazione nei trial di fase I e II. Settecento sono i farmaci in pipeline oncologica. Ecco ci\u00f2 che emerge dal report di IQVIA&#8230;<\/p>\n","protected":false},"author":297440,"featured_media":10701,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[141],"tags":[],"class_list":["post-10698","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global Oncology Trends. L\u2019ultimo report di IQVIA Institute - Frezza Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Oncology Trends. L\u2019ultimo report di IQVIA Institute - Frezza Partners\" \/>\n<meta property=\"og:description\" content=\"Photo by Stephen Walker &nbsp; Pi\u00f9 di 700 aziende sono impegnate oggi nella ricerca oncologica. In particolare risultano quattordici le top companies con la maggior parte della pipeline focalizzata su tale area (almeno un terzo).\u00a0 Per quanto concerne gli studi di ricerca, questi sono concentrati specialmente su immunoterapie, con circa trecento molecole e sessanta meccanismi d\u2019azione in valutazione nei trial di fase I e II. Settecento sono i farmaci in pipeline oncologica. Ecco ci\u00f2 che emerge dal report di IQVIA...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/\" \/>\n<meta property=\"og:site_name\" content=\"Frezza Partners\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-28T12:07:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/stephen-walker-572414-unsplash-1-1024x667.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"667\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frezza Partners\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frezza Partners\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/global-oncology-trends-lultimo-report-di-iqvia-institute\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/global-oncology-trends-lultimo-report-di-iqvia-institute\\\/\"},\"author\":{\"name\":\"Frezza Partners\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"headline\":\"Global Oncology Trends. L\u2019ultimo report di IQVIA Institute\",\"datePublished\":\"2018-05-28T12:07:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/global-oncology-trends-lultimo-report-di-iqvia-institute\\\/\"},\"wordCount\":346,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/global-oncology-trends-lultimo-report-di-iqvia-institute\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2018\\\/05\\\/stephen-walker-572414-unsplash-1.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/frezzapartners.com\\\/global-oncology-trends-lultimo-report-di-iqvia-institute\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/global-oncology-trends-lultimo-report-di-iqvia-institute\\\/\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/global-oncology-trends-lultimo-report-di-iqvia-institute\\\/\",\"name\":\"Global Oncology Trends. L\u2019ultimo report di IQVIA Institute - Frezza Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/global-oncology-trends-lultimo-report-di-iqvia-institute\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/global-oncology-trends-lultimo-report-di-iqvia-institute\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2018\\\/05\\\/stephen-walker-572414-unsplash-1.jpg\",\"datePublished\":\"2018-05-28T12:07:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/global-oncology-trends-lultimo-report-di-iqvia-institute\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/frezzapartners.com\\\/global-oncology-trends-lultimo-report-di-iqvia-institute\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/global-oncology-trends-lultimo-report-di-iqvia-institute\\\/#primaryimage\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2018\\\/05\\\/stephen-walker-572414-unsplash-1.jpg\",\"contentUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2018\\\/05\\\/stephen-walker-572414-unsplash-1.jpg\",\"width\":5000,\"height\":3256},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/global-oncology-trends-lultimo-report-di-iqvia-institute\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/frezzapartners.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Oncology Trends. L\u2019ultimo report di IQVIA Institute\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/\",\"name\":\"Frezza Partners\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/frezzapartners.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\",\"name\":\"Frezza Partners\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/en\\\/author\\\/fr3zz4partn3rs\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Oncology Trends. L\u2019ultimo report di IQVIA Institute - Frezza Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/","og_locale":"en_US","og_type":"article","og_title":"Global Oncology Trends. L\u2019ultimo report di IQVIA Institute - Frezza Partners","og_description":"Photo by Stephen Walker &nbsp; Pi\u00f9 di 700 aziende sono impegnate oggi nella ricerca oncologica. In particolare risultano quattordici le top companies con la maggior parte della pipeline focalizzata su tale area (almeno un terzo).\u00a0 Per quanto concerne gli studi di ricerca, questi sono concentrati specialmente su immunoterapie, con circa trecento molecole e sessanta meccanismi d\u2019azione in valutazione nei trial di fase I e II. Settecento sono i farmaci in pipeline oncologica. Ecco ci\u00f2 che emerge dal report di IQVIA...","og_url":"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/","og_site_name":"Frezza Partners","article_published_time":"2018-05-28T12:07:32+00:00","og_image":[{"width":1024,"height":667,"url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/stephen-walker-572414-unsplash-1-1024x667.jpg","type":"image\/jpeg"}],"author":"Frezza Partners","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Frezza Partners","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/#article","isPartOf":{"@id":"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/"},"author":{"name":"Frezza Partners","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"headline":"Global Oncology Trends. L\u2019ultimo report di IQVIA Institute","datePublished":"2018-05-28T12:07:32+00:00","mainEntityOfPage":{"@id":"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/"},"wordCount":346,"commentCount":0,"image":{"@id":"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/stephen-walker-572414-unsplash-1.jpg","articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/","url":"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/","name":"Global Oncology Trends. L\u2019ultimo report di IQVIA Institute - Frezza Partners","isPartOf":{"@id":"https:\/\/frezzapartners.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/#primaryimage"},"image":{"@id":"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/stephen-walker-572414-unsplash-1.jpg","datePublished":"2018-05-28T12:07:32+00:00","author":{"@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"breadcrumb":{"@id":"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/#primaryimage","url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/stephen-walker-572414-unsplash-1.jpg","contentUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/stephen-walker-572414-unsplash-1.jpg","width":5000,"height":3256},{"@type":"BreadcrumbList","@id":"https:\/\/frezzapartners.com\/global-oncology-trends-lultimo-report-di-iqvia-institute\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/frezzapartners.com\/"},{"@type":"ListItem","position":2,"name":"Global Oncology Trends. L\u2019ultimo report di IQVIA Institute"}]},{"@type":"WebSite","@id":"https:\/\/frezzapartners.com\/#website","url":"https:\/\/frezzapartners.com\/","name":"Frezza Partners","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/frezzapartners.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0","name":"Frezza Partners","url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/"}]}},"_links":{"self":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/10698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/users\/297440"}],"replies":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/comments?post=10698"}],"version-history":[{"count":0,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/10698\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media\/10701"}],"wp:attachment":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media?parent=10698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/categories?post=10698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/tags?post=10698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}